No insider buying and all institutional dumping. With all that said I'm sorry to say but there is no stop over five dollars in that event. Time to take your profits and move on because this thing is going to go down like there is no tomorrow, I'm just hoping that It was no false data that made so many people to buy Stock shares and Panic buying. If it reaches over eight dollars again I could be wrong but right now it's not a good time to home at these levels it's just been floating around five dollars
If you think it won't go back to $120 Look at Bristol Myers $78 $130 billion company with only $0.62 profits this corner up 2% growth. Gilead $3.02 a quarter,$100 billion market cap. Good luck with your inflated on the bio text I'm sticking with Gilead and buying more and more throughout many years to come on my long-term investment thank you so so much
This should be very interesting to get an update on the best prostate drug available from SPHS
This company has no many problems and will show a tremendous loss coming, you should pull the plug now. I've seen this before. I sold mine and will buy back way lower people so sell here please, thanks
There isn't any shorting with SPHS because this is a good company 0.61 is probably a key to buy this company the shorts will come when it maybe $10 or higher but with this great data recently they are gone and buyer are waiting for what? Probably when it goes to $3 they will pile in to get to $10 like always, so just buy and be quiet.
H.C. Wainwright’s Swayampakula Ramakanth believes if the VTS gene therapy platform is successfully developed by Vascular Biogenics Ltd
, it could revolutionize the multi-billion dollar angiogenesis inhibitor market.
Ramakanth initiated coverage of the company with a Buy rating and price target of $11.
The analyst mentioned that the company is developing a novel anti-angiogenesis therapy for solid tumors, and that compared to the currently available anti-angiogenesis drugs, Vascular Biogenics’ gene therapy offers several advantages, such as lower toxicity, tissue-specific activity and simpler dosing regimen.
“Currently, we expect VBL’s lead gene therapy product, VB-111, to reach the market in 2019 and achieve risk-adjusted annual sales of $386M by 2026,” Ramakanth stated.
Related Link: The Market In 5 Minutes: Stocks Start To Recover From Brexit Onslaught
VB-111 has already demonstrated significant efficacy in the Phase 2 study in recurrent glioblastoma multiforme (rGBM), which is a highly aggressive yet difficult to treat brain tumor.
Vascular Biogenics initiated a pivotal Phase 3 trial for VB-111 in rGBM in 2H15 and the analyst believes that this could be the first drug to receive approval for rGBM since 2009.
“In addition to the GBM program, the company is also investigating the use of VB-111 for the treatment of ovarian and thyroid cancers in mid-stage studies,” according to the H.C. Wainwright report.
Ramakanth pointed out there were several upcoming catalysts for the company, including the expected top-line results from the GLOBE study in 1Q18.
The other catalysts that could drive share price appreciation include “1) full results from the Phase 2 study in thyroid cancer (4Q16); 2) initiation of the Phase 2b study in ovarian cancer (late-2016); and 3) interim analysis of the GLOBE study (1H17).”
In addition, Vascular Biogenics has several follow-on products in its pipeline.
charging stations I needed in every city to charge the Tesla car and if you go on Google images you would see solar city charging stations I think Elon seen the future